Treatment non-response to boswellic acids is associated with MIR-302B expression in CD4+T cells of relapsing remitting multiple sclerosis patients in the Saba proof-of-concept trial

Authors
Category Primary study
JournalJOURNAL OF NEUROIMMUNOLOGY
Year 2014
This article has no abstract
Epistemonikos ID: d963ffc49161cebbb4b37d345b70bf75660269a7
First added on: Feb 07, 2025